

Author: Peattie Robert Pike Daniel Yu Bolan Cai Shenshen Shu Xiao Zheng Prestwich Glenn Firpo Matthew Fisher Robert
Publisher: Informa Healthcare
ISSN: 1521-0464
Source: Drug Delivery, Vol.15, Iss.6, 2008-08, pp. : 389-397
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The hypothesis that incorporation of small amounts (0.3% w/w) of modified heparin in thiol-modified hyaluronan or HA and gelatin hydrogels would regulate release of cytokine growth factors (GFs) from those gels has been investigated in vitro. In addition, the physiologic response to gel implantation has been evaluated in vivo. Tests were performed with 6 GFs: basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), keratinocyte growth factor, platelet-derived growth factor-AA (PDGF), and transforming growth factor-β 1. Release profiles for all 6 over several weeks were well fit by first order exponential kinetics (R2 > 0.9 for all cases). The most remarkable result of the experiment was a dramatic variation in the total mass ultimately released, which varied from as much as 90.2% of the initial load for bFGF to as little as 1.8% for PDGF, a 45-fold difference. Furthermore, gels containing either VEGF of Ang-1 produced twice the vascularization response in vivo as gels not containing a growth factor. Thus, those GFs maintained strong physiologic effectiveness.
Related content








Controlled Release of Plasmid DNA from Hyaluronan Nanoparticles
Current Drug Delivery, Vol. 8, Iss. 4, 2011-07 ,pp. :


Hyalograft® C: Hyaluronan-Based Scaffolds in Tissue-Engineered Cartilage
Cells Tissues Organs, Vol. 186, Iss. 2, 2007-05 ,pp. :